Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems, Inc. (NYSE: INSP) is a medical technology company focused on minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. This news page aggregates company announcements, clinical updates, and financial disclosures so readers can follow how Inspire therapy and the Inspire V system are progressing in clinical practice and the marketplace.
Inspire regularly issues earnings releases and financial guidance, including preliminary and unaudited revenue ranges, full-year outlooks, and discussions of non-GAAP measures such as adjusted net income and adjusted EBITDA. Investors can track how revenue tied to Inspire therapy evolves over time, as well as information about share repurchase authorizations and tax-related items disclosed in Form 8-K filings and accompanying press releases.
Because Inspire’s core business is neurostimulation-based treatment for moderate to severe obstructive sleep apnea, a significant portion of its news flow centers on clinical data and product evolution. The company publishes outcomes from studies of the Inspire V system, including procedure success rates, reductions in disease severity, and patient adherence, and presents these results at medical meetings such as the American Academy of Otolaryngology–Head and Neck Surgery and the International Surgical Sleep Society.
Corporate governance and leadership changes are also covered, including announcements about the transition of the Chief Financial Officer role, executive employment agreements, and retirement plans for senior leaders. In addition, Inspire frequently reports on its participation in major healthcare and investor conferences, where management discusses business performance, reimbursement developments, and strategic priorities.
By reviewing this news feed, followers of INSP stock can see how Inspire communicates its financial performance, clinical evidence, regulatory and reimbursement context, and leadership decisions over time, all drawn from company-issued releases and related SEC filings.
Inspire Medical Systems (NYSE: INSP) reported Q1 2026 revenue of $204.6 million (up 1.6% YoY), GAAP diluted EPS of $(0.39) and adjusted diluted EPS of $0.10. Operating cash flow was $12.8 million and gross margin rose 180 bps to 86.5%. The company narrowed full‑year revenue guidance to $825–$875 million (down 4%–10% vs 2025) and expects adjusted diluted EPS of $0.75–$1.25, with an assumed adjusted tax rate of 27%–29%.
The company cited coding and reimbursement disruption and implementation of the WISeR program as near‑term headwinds and anticipates challenges to persist through 2026 while targeting a return to revenue growth in 2027.
Inspire Medical Systems (NYSE: INSP) will present at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, 2026 at 11:00 a.m. Eastern Time. The presentation will be available via a live webcast and a replay will be accessible in the company's Event Archive for two weeks.
Inspire Medical Systems (NYSE: INSP) will report first quarter 2026 financial results after market close on Monday, May 4, 2026.
A management conference call will begin at 5:00 p.m. Eastern Time the same day and will be webcast via the company's Investor Relations page. Registration is required to ask questions; registrants receive dial-in details and a unique access code. The company recommends registering at least 10 minutes before the call. A replay will be available approximately two hours after the event and archived on the Investor Relations site for two weeks.
Inspire Medical Systems (NYSE: INSP) announced its management will present at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026 at 1:30 p.m. ET. The presentation will be available via live webcast and a replay will be posted for two weeks in the Event Archive.
Investors can access the live webcast and the two-week replay on Inspire’s investor website Event Archive at the provided URL.
Inspire Medical Systems (NYSE: INSP) reported strong 4Q25 and full-year 2025 results, driven by the commercial launch of the Inspire V system and FDA 3.0T MRI compatibility.
Highlights include 4Q revenue $269.1M (+12%), FY revenue $912.0M (+14%), 4Q diluted EPS $4.66, FY diluted EPS $4.89, and operating cash flow of $117.0M for 2025. The company revised 2026 revenue guidance to $950M–$1.0B and noted coding clarification to CPT 64582 with a -52 modifier may affect physician reimbursement.
Inspire Medical Systems (NYSE: INSP) reported preliminary, unaudited revenue of $268.9M–$269.1M for Q4 2025 (≈12% YoY) and $911.8M–$912.0M for full year 2025 (≈14% YoY). The company provided initial 2026 revenue guidance of $1,003M–$1,013M (10%–11% above 2025). Management cited momentum from the Inspire V system launch and noted recent reimbursement developments, but said guidance excludes any reimbursement contribution. Results are preliminary and subject to change pending year-end close and audit.
Inspire Medical Systems (NYSE: INSP) will report fourth quarter and full year 2025 financial results after market close on Wednesday, February 11, 2026. Management will host a conference call at 5:00 p.m. Eastern Time to discuss results and recent business developments.
A live webcast will be available on the company’s Investor Relations page and registration is required to ask questions; registrants receive dial-in details and a unique access code. The company recommends registering at least 10 minutes before the call. A replay will be posted approximately two hours after the event and archived on the Investor Relations site for two weeks.
Inspire Medical Systems (NYSE: INSP) announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 12:45 p.m. Eastern Time.
The presentation will be available via a live webcast, with a replay accessible for two weeks after the event in the Event Archive on Inspire’s investor website: https://investors.inspiresleep.com.
Inspire Medical Systems (NYSE: INSP) announced its management team will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 11:30 a.m. Eastern Time.
The presentation will be available via a live webcast and a replay will be hosted for two weeks in the Event Archive on Inspire’s investor website at https://investors.inspiresleep.com.
Inspire Medical Systems (NYSE: INSP) reported third quarter 2025 results on November 3, 2025, with Q3 revenue of $224.5M (up 10% YoY) and gross margin of 85.8%. The company reported net income of $9.9M and adjusted net income of $11.2M, with diluted EPS of $0.34 and adjusted diluted EPS of $0.38. Operating cash flow for Q3 was $68.5M. Management completed $50M of share repurchases and reported strong early adoption of the Inspire V system with positive clinical and procedural results. Inspire reaffirmed 2025 revenue guidance of $900M–$910M, maintained gross margin guidance of 84%–86%, and raised diluted net income per share guidance to $0.90–$1.00 from $0.40–$0.50.